Axsome CRESCENDO survey: 77% of treated NT1 patients still have cataplexy; 74% cognitive impairment

Axsome Therapeutics, Inc.

77% of treated NT1 patients continue to experience cataplexy attacks despite current therapy.
64% have excessive daytime sleepiness (ESS>10); 74% exhibit cognitive impairment (BC-CCI≥5).
Depression and anxiety reported by 45% and 57% of patients, respectively.
Survey included 203 adults; top treatments were wake-promoting agents (53%), oxybates (47%), stimulants (42%).
Axsome plans to present detailed CRESCENDO results at upcoming scientific meetings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.